These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 8386406)

  • 61. Significance of cytomegalovirus infection in renal transplantation.
    Solà R; Díaz JM; Guirado L; Ravella N; Vila L; Sainz Z; Gich I; Picazo M; García R; Abreu E; Ortiz F; Alcaraz A
    Transplant Proc; 2003 Aug; 35(5):1753-5. PubMed ID: 12962782
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Management of cytomegalovirus infection by weekly surveillance after renal transplant: analysis of cost, rejection and renal function.
    Geddes CC; Church CC; Collidge T; McCruden EA; Gillespie G; Matthews E; Hainmueller A; Briggs JD
    Nephrol Dial Transplant; 2003 Sep; 18(9):1891-8. PubMed ID: 12937240
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Leflunomide as a rescue treatment in ganciclovir-resistant cytomegalovirus infection in a seronegative renal transplant recipient--a case report.
    Ciszek M; Mucha K; Foroncewicz B; Chmura A; Pączek L
    Ann Transplant; 2014 Jan; 19():60-3. PubMed ID: 24481271
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Cytomegalovirus disease in renal allograft recipients: a prospective study of the clinical features, risk factors and impact on renal transplantation.
    Peterson PK; Balfour HH; Marker SC; Fryd DS; Howard RJ; Simmons RL
    Medicine (Baltimore); 1980 Jul; 59(4):283-300. PubMed ID: 6248718
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Evaluation of Low- Versus High-dose Valganciclovir for Prevention of Cytomegalovirus Disease in High-risk Renal Transplant Recipients.
    Gabardi S; Asipenko N; Fleming J; Lor K; McDevitt-Potter L; Mohammed A; Rogers C; Tichy EM; Weng R; Lee RA
    Transplantation; 2015 Jul; 99(7):1499-505. PubMed ID: 25643140
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Impact of HLA-G 14-bp polymorphism on acute rejection and cytomegalovirus infection in kidney transplant recipients from northwestern China.
    Jin ZK; Xu CX; Tian PX; Xue WJ; Ding XM; Zheng J; Ding CG; Ge GQ; Mao TC; Lin Y
    Transpl Immunol; 2012 Oct; 27(2-3):69-74. PubMed ID: 22750489
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Absence of association between cytomegalovirus infection and obliterative transplant arteriopathy in renal allograft rejection.
    Nadasdy T; Smith J; Laszik Z; Waner JL; Johnson LD; Silva FG
    Mod Pathol; 1994 Apr; 7(3):289-94. PubMed ID: 8058700
    [TBL] [Abstract][Full Text] [Related]  

  • 68. [Factors influencing prevalence and clinical course of cytomegalovirus (CMV) infection in kidney transplant patients].
    Szymczakiewicz-Multanowska AM; Kuźniewski M; Zawilińska B; Zgórniak-Nowosielska I; Uracz D; Ignacak E; Betkowska-Prokop A; Sułowicz W
    Przegl Lek; 2001; 58(7-8):772-7. PubMed ID: 11769385
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Severe graft rejection, increased immunosuppression, and active CMV infection in renal transplantation.
    von Müller L; Schliep C; Storck M; Hampl W; Schmid T; Abendroth D; Mertens T
    J Med Virol; 2006 Mar; 78(3):394-9. PubMed ID: 16419118
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Latent cytomegalovirus infection is an independent risk factor for late graft failure in renal transplant recipients.
    van Ree RM; de Vries AP; Zelle DM; de Vries LV; Oterdoom LH; Gans RO; Schouten JP; Lems SP; van Son WJ; Bakker SJ
    Med Sci Monit; 2011 Nov; 17(11):CR609-617. PubMed ID: 22037739
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Induction immunosuppression with antilymphocyte globulin or OKT3 in cadaver kidney transplantation. Results of a single institution prospective randomized trial.
    Hanto DW; Jendrisak MD; So SK; McCullough CS; Rush TM; Michalski SM; Phelan D; Mohanakumar T
    Transplantation; 1994 Feb; 57(3):377-84. PubMed ID: 8108873
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Increased infections associated with the use of OKT3 for treatment of steroid-resistant rejection in renal transplantation.
    Oh CS; Stratta RJ; Fox BC; Sollinger HW; Belzer FO; Maki DG
    Transplantation; 1988 Jan; 45(1):68-73. PubMed ID: 3276066
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Cytomegalovirus infection in living donor liver transplant recipients significantly impacts the early post-transplant outcome: A single center experience.
    Yadav SK; Saigal S; Choudhary NS; Saha S; Sah JK; Saraf N; Kumar N; Goja S; Rastogi A; Bhangui P; Soin AS
    Transpl Infect Dis; 2018 Aug; 20(4):e12905. PubMed ID: 29668120
    [TBL] [Abstract][Full Text] [Related]  

  • 74. The influence of HLA matching on cytomegalovirus hepatitis and chronic rejection after liver transplantation.
    Mañez R; White LT; Linden P; Kusne S; Martin M; Kramer D; Demetris AJ; Van Thiel DH; Starzl TE; Duquesnoy RJ
    Transplantation; 1993 May; 55(5):1067-71. PubMed ID: 8388584
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Long-term outcome of cytomegalovirus infection in simultaneous pancreas-kidney transplant recipients without ganciclovir prophylaxis.
    Rayes N; Seehofer D; Kahl A; Kokott S; Pratschke J; Frei U; Neuhaus P
    Transpl Int; 2007 Nov; 20(11):974-81. PubMed ID: 17680782
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Infectious complications in kidney transplant recipients: a single-center experience.
    Charfeddine K; Zaghden S; Kharrat M; Kamoun K; Jarraya F; Hachicha J
    Transplant Proc; 2005; 37(6):2823-5. PubMed ID: 16182820
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Effect of cytomegalovirus on an experimental model of chronic renal allograft rejection under triple-drug treatment in the rat.
    Lautenschlager I; Soots A; Krogerus L; Kauppinen H; Saarinen O; Bruggeman C; Ahonen J
    Transplantation; 1997 Aug; 64(3):391-8. PubMed ID: 9275101
    [TBL] [Abstract][Full Text] [Related]  

  • 78. A prospective study of the natural course of cytomegalovirus infection and disease in renal allograft recipients.
    Sagedal S; Nordal KP; Hartmann A; Degré M; Holter E; Foss A; Osnes K; Leivestad T; Fauchald P; Rollag H
    Transplantation; 2000 Oct; 70(8):1166-74. PubMed ID: 11063335
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Soluble interleukin-2 receptor (S IL-2R) in renal and pancreatic transplantation.
    Touraine F; Malcus C; Pouteil-Noble C; Touraine JL
    Eur Cytokine Netw; 1991; 2(1):47-50. PubMed ID: 1651783
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Cytomegalovirus-specific CD8+ T cells do not develop in all renal transplant patients at risk of virus infection.
    Christmas SE; Halliday D; Lawton N; Wang H; Abdalla I; Masters J; Hassan RL; Hart IJ; Khan N; Smith J; Hammad A; Bakran A
    Transpl Immunol; 2009 Dec; 22(1-2):99-104. PubMed ID: 19635559
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.